GSK and SCYNEXIS announce an exclusive agreement to commercialise and further develop Brexafemme (ibrexafungerp), a novel, first-in-class medicine to treat fungal infection
GSK and SCYNEXIS announce an exclusive agreement to commercialise and further develop Brexafemme (ibrexafungerp), a novel, first-in-class medicine to treat fungal infection
Provider: View Press Release Type: Link Title: GSK and SCYNEXIS announce an exclusive agreement to commercialise and further develop Brexafemme (ibrexafungerp), a novel, first-in-class medicine to treat fungal infection | GSK Description: Brexafemme complements GSK’s industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasis.
Medicines Patent Pool signs sublicences with Aurobindo, Cipla and Viatris to produce generic versions of ViiV Healthcare’s innovative long-acting HIV prevention medicine
Medicines Patent Pool signs sublicences with Aurobindo, Cipla and Viatris to produce generic versions of ViiV Healthcare’s innovative long-acting HIV prevention medicine
Provider: View Press Release Type: Link Title: Medicines Patent Pool signs sublicences with Aurobindo, Cipla and Viatris to produce generic versions of ViiV Healthcare’s innovative long-acting HIV prevention medicine | GSK Description: Licences should enable potentially millions of people living in areas most impacted by HIV to access innovative prevention medicine.
Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone
Phase III RUBY clinical trial demonstrates potential of Jemperli (dostarlimab) plus chemotherapy to redefine the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone
China National Medical Products Administration accepts regulatory submission for Nucala (mepolizumab) in severe eosinophilic asthma
Provider: View Press Release Type: Link Title: China National Medical Products Administration accepts regulatory submission for Nucala (mepolizumab) in severe eosinophilic asthma | GSK Description: The China National Medical Products Administration (NMPA) has accepted for review a new drug application for Nucala (mepolizumab)
GSK announces positive pivotal phase III data for 5-in-1 Meningococcal ABCWY vaccine candidate
Provider: View Press Release Type: Link Title: GSK announces positive pivotal phase III data for 5-in-1 Meningococcal ABCWY vaccine candidate | GSK Description: MenABCWY combination vaccine candidate met all its primary endpoints of the pivotal phase III clinical trial
US FDA Advisory Committee votes to support effectiveness and safety of GSK’s respiratory syncytial virus older adult vaccine candidate
Provider: View Press Release Type: Link Title: US FDA Advisory Committee votes to support effectiveness and safety of GSK’s respiratory syncytial virus older adult vaccine candidate | GSK Description: Committee votes unanimously that the data support the effectiveness of the vaccine and 10-2 that the data support the safety of the vaccine
